Recent studies have suggested PD-L1 expression as a potential biomarker; they have reported that ICI combined with angiogenesis inhibitors improved the outcome in patients with positive PD-L1 expression affected by renal cell carcinoma, NSCLC, advanced HER2-positive breast cancer and untreated, unresectable hepatocellular carcinoma (260, 269–273). The gene discussed is CD274; the disease is breast cancer.